SINGAPORE | Zuellig Pharma, a leading healthcare solutions company in Asia, has signed a 10-year commercialisation partnership with Austria-based Institut AllergoSan.
Institut AllergoSan is a research and development company that has specialised in products made from natural substances such as probiotic bacteria, plant extracts, and minerals.
Under this partnership, Zuellig Pharma will provide a broad spectrum of commercialisation support, including product registration, sales and marketing, and warehousing and distribution services, to bring OMNi-BiOTiC, one of Institut AllergoSan’s leading probiotic brands, to key Asian markets.
“Our consumer healthcare segment will be one of the key growth drivers in our business over the coming years. This partnership represents a significant step in our commitment to delivering innovative and accessible healthcare solutions to Asian patients,” said John Graham, Group CEO of Zuellig Pharma.
“With a fast-growing probiotics market in Asia, the comprehensive and tailored solutions offered through our commercialisation division, ZP Therapeutics, will help our partners expand their footprint to meet greater consumer demand for gut health products in this region.”
Both companies will leverage their combined expertise to enhance consumers' well-being and advance the mission of making healthcare more accessible.
“We are dedicated to supporting consumers’ pursuit of a healthier, more vital self and offer medically relevant probiotic supplements that target specific health needs and deliver clinically backed results,” said Anita Frauwallner, founder and CEO of Institut AllergoSan.
“OMNi-BiOTiC is the top-selling probiotic brand in all German-speaking markets in Europe, such as Austria, Germany and Switzerland, and we look forward to working closely with Zuellig Pharma to bring these innovative products to everybody in Asia who wants to promote an active, healthy life.”
Zuellig Pharma has planned to launch OMNi-BiOTiC in Indonesia, the Philippines and Taiwan in 2025, followed by other key markets.
More news here.
